Product Description
Mechanisms of Action: Free Radical Inducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Italy | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Quintiles IMS
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Cholangiocarcinoma
Phase 2: Squamous Cell Carcinoma|Head and Neck Cancer|Ductal Carcinoma|Nasopharyngeal Cancer|Oncology Unspecified|Klatskin Tumor|Cholangiocarcinoma
Phase 1: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01854684 |
I 228112 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2018-09-04 |
2022-07-23 |
Primary Endpoints|Treatments |
|
NCT01637376 |
NCT01637376 | P1 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2014-01-01 |
2019-03-19 |
Treatments |
|
2004-004452-39 |
2004-004452-39 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT03003065 |
PDT | P2 |
Completed |
Klatskin Tumor|Cholangiocarcinoma |
2023-04-12 |
2023-08-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2005-004866-17 |
Foscan-PDT-protocol for BDC | P2 |
Completed |
Oncology Unspecified |
2012-12-31 |
2022-03-12 |
Treatments |
|
NCT01016002 |
Foscan 1/2005 | P2 |
Unknown status |
Ductal Carcinoma |
2011-12-01 |
2019-03-19 |
Treatments |
|
NCT01086488 |
FOSCAN | P2 |
Unknown status |
Nasopharyngeal Cancer |
2011-09-01 |
2019-03-19 |
Treatments |
|
NCT01415986 |
UAMS IRB 114294 | P2 |
Terminated |
Squamous Cell Carcinoma|Head and Neck Cancer |
2011-08-01 |
2019-03-19 |
Treatments |
|
NCT00003856 |
CDR0000067019 | P2 |
Unknown status |
Squamous Cell Carcinoma|Head and Neck Cancer |
None |
2019-03-21 |
Treatments |
|
2022-500107-50-00 |
CARP | P4 |
Recruiting |
Cholangiocarcinoma |
2027-12-31 |
2025-05-02 |
Treatments |